Table 1.
LncRNAs significantly associated with the disease free survival in the training cohort patients (N = 150)
| Ensembl | Gene Symbol | P value a | Hazard Ratio a | Coefficient b | associated diseases | Description | Reference |
|---|---|---|---|---|---|---|---|
| ENSG00000253417 | LINC02159 | < 0.001 | 2.85 | 0.069 | colorectal cancer, melanoma, head and neck squamous cell carcinoma | long intergenic non-protein coding RNA 2159 | [1–3] |
| ENSG00000272205 | < 0.001 | 2.47 | 0.233 | NR | NR | ||
| ENSG00000269894 | < 0.001 | 2.48 | 0.092 | NR | NR | ||
| ENSG00000275437 | < 0.001 | 4.78 | 0.083 | NR | NR | ||
| ENSG00000223392 | CLDN10-AS1 | < 0.001 | 1.82 | 0.278 | atherogenesis, lung adenocarcinoma, colorectal cancer, thyroid cancer, cholangiocarcinoma, colon adenocarcinoma | CLDN10 antisense RNA 1 | [4–6, 20] |
| ENSG00000248596 | LOC643201 | < 0.001 | 1.91 | 0.335 | colorectal cancer | centrosomal protein 192 kDa pseudogene | [5] |
| ENSG00000268201 | < 0.001 | 1.98 | 0.330 | NR | NR | ||
| ENSG00000247675 | LRP4-AS1 | < 0.001 | 7.36 | 0.567 | breast cancer, pancreatic neuroendocrine tumour | LRP4 antisense RNA 1 | [7] |
| ENSG00000231918 | LOC730100 | < 0.001 | 2.19 | 0.339 | glioma | uncharacterized LOC730100 | [8] |
| ENSG00000259834 | < 0.001 | 0.28 | −0.721 | NR | NR | ||
| ENSG00000234129 | 0.001 | 9.68 | 0.272 | NR | NR | ||
| ENSG00000269974 | 0.001 | 2.24 | 0.007 | NR | NR | ||
| ENSG00000254887 | LOC100505622 | 0.002 | 0.05 | −0.735 | gastric cancer | uncharacterized LOC100505622 | [12] |
| ENSG00000259974 | LINC00261 | 0.003 | 0.69 | − 0.187 | hepatocellular carcinoma, endometrial carcinoma, non-small cell lung cancer, colon cancer, esiohageal cancer, endometriosis, choriocarcinoma, gastric cancer, esophageal cancer, lung epithelial homeostasis, endoderm differentiation | long intergenic non-protein coding RNA 261 | [13–19, 25–27] |
| ENSG00000236366 | LOC153910 | 0.003 | 1.65 | 0.232 | lung function development, chronic obstructive pulmonary disease (COPD) and cardiovascular diseases (CVD) | uncharacterized LOC153910 | [3, 21–24] |
| ENSG00000275223 | 0.003 | 1.56 | 0.024 | NR | NR | ||
| ENSG00000253406 | 0.004 | 967.38 | 1.878 | NR | NR | ||
| ENSG00000232079 | LINC01697 | 0.009 | 1.53 | 0.142 | lung squamous cell carcinoma, gastric cancer, gastric adenocarcinoma, breast cancer | long intergenic non-protein coding RNA 1697 | [9–11] |
| ENSG00000273837 | 0.012 | 0.59 | −0.025 | NR | NR | ||
| ENSG00000255980 | LOC102724265 | 0.017 | 10.02 | 0.125 | NR | uncharacterized LOC102724265 | |
| ENSG00000267905 | 0.018 | 1.5 | 0.032 | NR | NR | ||
| ENSG00000176912 | TYMSOS | 0.023 | 1.28 | 0.038 | NR | TYMS opposite strand | |
| ENSG00000254333 | NDST1-AS1 | 0.032 | 1.21 | 0.044 | NR | NDST1 antisense RNA 1 | |
| ENSG00000231246 | LINC02884 | 0.033 | 0.17 | −0.041 | NR | long intergenic non-protein coding RNA 2884 | |
| ENSG00000234283 | 0.047 | 0.39 | −0.459 | NR | NR |
NR not reported
a Derived from the univariable Cox proportional hazards regression analysis in the 150 training cohort patients
b Derived from the LASSO regression analysis in the 150 training cohort patients
Please refer to the supplementary material for references citation